« Back to Record
Citation APA

Rescigno, P., Dolling, D., Conteduca, V., Rediti, M., Bianchini, D., Lolli, C., Ong, M., Li, H., Omlin, A., Schmid, S., Caffo, O., Zivi, A., Pezaro, C. C., Morley, C., Olmos, D., Romero-Laorden, N., Castro, E., Saez, M. I., Mehra, N., Smeenk, S., Sideris, S., Gil, T., Banks, P., Sandhu, S. S., Sternberg, C. N., De Giorgi, U., & De Bono, J. S. (2019). Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. European Urology Oncology. doi:10.1016/j.euo.2019.06.008


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/291318

Rescigno, P., Dolling, D., Conteduca, V., Rediti, M., Bianchini, D., Lolli, C., Ong, M., Li, H., Omlin, A., Schmid, S., Caffo, O., Zivi, A., Pezaro, C. C., Morley, C., Olmos, D., Romero-Laorden, N., Castro, E., Saez, M. I., Mehra, N., Smeenk, S., Sideris, S., Gil, T., Banks, P., Sandhu, S. S., Sternberg, C. N., De Giorgi, U., & De Bono, J. S. (2019). Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. European Urology Oncology. doi:10.1016/j.euo.2019.06.008